Forte Biosciences, Inc. (FBRX)

Market Cap	527.57M +1,186.3%
Revenue (ttm)	n/a
Net Income	-75.86M
EPS	-4.25
Shares Out	24.44M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,967
Open	21.79
Previous Close	22.00
Day's Range	20.69 - 22.35
52-Week Range	7.00 - 35.80
Beta	3.00
Analysts	Strong Buy
Price Target	63.75 (+195.89%)
Earnings Date	May 11, 2026

About FBRX

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Paul A. Wagner
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: FBRX
• Website: https://www.fortebiorx.com

Analyst Summary

According to 5 analysts, the average rating for FBRX stock is "Strong Buy." The 12-month stock price target is $63.75, which is an increase of 195.89% from the latest price.

Price Target

$63.75

(195.89% upside)

Analyst Consensus: Strong Buy